BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang W, Jiang C, Wang Z, Zhang J, Mao X, Chen G, Yao X, Liu C. Cyclocarya paliurus extract attenuates hepatic lipid deposition in HepG2 cells by the lipophagy pathway. Pharmaceutical Biology 2020;58:838-44. [DOI: 10.1080/13880209.2020.1803365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chhimwal J, Goel A, Sukapaka M, Patial V, Padwad Y. Phloretin mitigates oxidative injury, inflammation and fibrogenic responses via restoration of autophagic flux in in-vitro and pre-clinical models of NAFLD. The Journal of Nutritional Biochemistry 2022. [DOI: 10.1016/j.jnutbio.2022.109062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li R, Zhu W, Huang P, Yang Y, Luo F, Dai W, Shen L, Pei W, Huang X. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomed Pharmacother 2021;141:111803. [PMID: 34146854 DOI: 10.1016/j.biopha.2021.111803] [Reference Citation Analysis]
3 Wang H, Tang C, Gao Z, Huang Y, Zhang B, Wei J, Zhao L, Tong X. Potential Role of Natural Plant Medicine Cyclocarya paliurus in the Treatment of Type 2 Diabetes Mellitus. J Diabetes Res 2021;2021:1655336. [PMID: 34988228 DOI: 10.1155/2021/1655336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zheng X, Zhang X, Liu Y, Zhu L, Liang X, Jiang H, Shi G, Zhao Y, Zhao Z, Teng Y, Pan K, Zhang J, Yin Z. Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. Journal of Functional Foods 2021;86:104686. [DOI: 10.1016/j.jff.2021.104686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li HY, Peng ZG. Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. Biochem Pharmacol 2022;197:114933. [PMID: 35093393 DOI: 10.1016/j.bcp.2022.114933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]